Skye Bioscience Inc (SKYE)

[Avoid]

On October 26, 2016, Nemus Bioscience, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) to sell 500 shares of Series C Convertible Preferred Stock (“Preferred Shares”), to certain accredited investors (as such terms are defined in the Securities Act of 1933 and the rules and regulations promulgated thereunder, all as amended, collectively, the “Purchasers”) at a purchase price of $1,000 for each Preferred Share for aggregate proceeds of $500,000 (the “Financing”). The designations, preferences and relative rights of the Series C Convertible Preferred Stock are specified in the Certificate of Designation of the Relative Rights and Preferences of the Series C Convertible Preferred Stock, which provides, among other things, that:

· The Preferred Shares have a stated value of $1,000 per share (“Stated Value”) and are convertible into shares of common stock at a conversion price of $0.40.

+- 1.250.000 shares, $500.000/ $0.40

this is less than 10% OS

Outstanding Shares 19,913,163 a/o Aug 12, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 5,005,713 a/o Mar 23, 2016

at a conversion price of $0.80.(current) only 625.000 shares.